236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (236)
- Addiction (3)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (3)
- Bone & Muscle (2)
- Cancer (10)
- COVID-19 (Coronavirus) (8)
- Diabetes (7)
- Ear, Nose and Throat (7)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (45)
- Heart Disease (18)
- Infectious Disease (11)
- Insomnia (1)
- Liver Disease (17)
- Lung Disease (2)
- Neurological Disorders (30)
- Nutrition (2)
- Obesity (8)
- Obstetrics & Gynecology (10)
- Pediatrics (15)
- Psychiatric Disorders (9)
- Rehabilitation (2)
- Stroke (2)
- Transplant (16)
- Vascular Conditions (1)
Displaying 1 - 5 of 5
Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Marzieh Majd, PharmD, PhD
Status: Currently Recruiting
We are recruiting adults with bipolar disorder, and adults with no psychiatric disorder, ages 18-60 years. As a participant in our study, you will be asked to attend one remote or in-person visit and one to two in-person visits. The following procedures will occur: Visit 1 (1 - 2.5 hrs): Clinical interview for overall psychiatric history as well as current…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether giving an investigational drug called C1 esterase inhibitor (C1INH) directly into the donor kidney before transplant can improve kidney function one year after surgery. At the time of the deceased donor kidney transplant, participants will be randomly assigned to received a kidney that has been treated with either C1INH or a…
Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Currently Recruiting
The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether a new investigational medicine called frexalimab can safely and effectively prevent kidney transplant rejection compared to tacrolimus, a standard medication currently used after transplant. Participants will be randomly assigned to receive either frexalimab (given by injection every 4 weeks) or tacrolimus (taken as capsules…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-transplant to prevent rejection. Participants will be…